Natalizumab versus fingolimod for patients with active relapsing-remitting multiple sclerosis: results from REVEAL, a prospective, randomised head-to-head study

RCT (n=108) found a lower risk of the primary endpoint (evolution of new on-treatment gadolinium-enhancing lesions to persistent black holes) for natalizumab vs fingolimod (11.5% vs 48.5% chance of developing ≥2 lesions at 24 weeks, HR=0.25; 95% CI 0.09–0.68).

BMJ Open